met een
Acco-aandeel
levenslang korting op Acco-uitgaven, kantoormateriaal en een selectie titels.
Inhoud
This timely reference summarizes the use, risks, dosages, interactions, and alternatives for all drugs commonly used in the catheterization laboratory. For ease of use, each chapter opens with a summary and includes cases and illustrations. Ron Waksman, MD, FACC. Associate Director, Division of Cardiology, Washington Hospital Center (WHC) and Director of Experimental Angioplasty & Emerging Technologies, Cardiovascular Research Institute(CRI) at WHC, Washington, DC USA Andrew E. Ajani, Australia CONTENTS 0.0 Elective PCI. 0.1 Optimal antithrombotic therapy. 0.1.1 Unfractionated heparin and ACT monitoring. 0.1.2 Alternative to unfractionated heparin. 0.1.2.1 LMWH. 0.1.2.2 direct thrombin inhibitor (bivarlirudin). 0.1.2.3 direct Xa antagonist (fondaparinux). 0.2 Optimal antiplatelet therapy. 0.2.1 Dual aspirin and thienopyridine therapy. - pre-treatment and dose. 0.2.2 When to use GP2B3A inhibitor and which one to use. - abciximab, tirofiban, eptifibatide. 0.2.3 Duration of Antiplatelet therapy with drug-eluting vs. bare-metal stents. 1.0 High risk PCI. 1.1 ACS (non ST elevation). 1.1.1 Upstream GP2B3A inhibitors. 1.1.2 Timing, loading dose and duration of clopidogrel therapy. 1.2 Diabetes mellitus. 1.2.1 Peri-procedural management. 1.3 Renal dysfunction. 1.3.1 Renal protective agents. - IV hydration, N-acetylcysteine, bicarbonate, fenoldopam. - Timing, route of administration and duration. 1.3.2 Radiocontrast induced nephropathy. 1.3.2.1 Ideal contrast agent. 1.3.3 Additional risk with other medications. - ACE inhibitors, NSAIDS, hypotensive medications (e.g. nitrates, BBlockers). 1.4 Cardiogenic shock. 1.4.1 Inotropic support. - adrenaline, noradrenaline, dopamine, dobutamine, milrinone, levosimendan, metaraminol. - summary of when to use which agent (ref. ACC/AHA STEMI guidelines). 1.4.2 Anticoagulation support for mechanical devices. - IABP, LVAD, Tandem Heart, Impaler etc. 2.0 Acute STEMI PCI. 2.1 Primary. - summary of optimal anticoagulation, GP2B3A, antiplatelet therapy (aspirin, clopidogrel). 2.2 Rescue. - summary of optimal anticoagulation, GP2B3A, antiplatelet therapy (aspirin, clopidogrel). 2.3 Facilitated. - summary of optimal anticoagulation, GP2B3A and lytic combinations in recent trials. 2.4 Adjunctive therapies. 2.4.1 GIK (glucose-insulin-potassium). 2.4.2 Complement inhibitor (Pexiluzimab). 2.4.3 Intracoronary vs. intravenous GP2B3A inhibitor. 2.4.4 High dose tirofiban. (Standard dose GP2B3A inhibitors for STEMI discussed in 2.1 and 2.2). 3.0 Optimal thrombolytic therapy (as primary therapy for STEMI). - alteplase, reteplase, streptokinase, or tenecteplase. 4.0 Special considerations in PCI. 4.1 Coronary spasm. 4.2 No reflow phenomenon. - IV GTN, GP2B3A inhibitor, nitroprusside, adenosine, verapamil, nicorandil. 4.3 Agents to optimise access of radial artery approach (i.e. nitrates, verapamil). 4.4 Arrhythmia Management. 4.4.1 Tachyarrhythmias management. - IV lignocaine, amiodarone, etc. 4.4.2 Bradyarrhythmias management. - IV atropine, adrenalin, indications for temporary pacing wire. 4.5 Coronary perforations. 4.5.1 Reversal of anticoagulation. - protamine. 4.5.2 Platelet and transfusion of blood products. 4.6 Oral anticoagulation issues in PCI. 4.6.1 Management of patients on anticoagulation undergoing diagnostic catheterisation and PCI. - prosthetic heart valves, AF and other indications. - use of UFH and LMWH as bridging therapy. - when to restart oral anticoagulation post procedure. 4.6.2 Indications for anticoagulation post PCI. - LV thrombus. - large anterior myocardial infarction. - triple (aspirin, clopidogrel and warfarin) vs. dual therapy. 4.7 Role of Antibiotic prophylaxis in PCI. 5.0 Post procedural pharmacotherapy. 5.1 Role of statins, beta-blocker, ACE inhibitors, aldosterone antagonist (epleronone). 5.1.1 ACS (include STEMI/NSTEMI). 5.1.2 Elective PCI. 6.0 Special considerations with antiplatelet therapy. 6.1 Antiplatelet therapy resistance: definition, diagnosis and clinical implications. 6.2 Potential drug-drug interactions. 6.2.1 Clopidogrel and statins. 6.2.2 Aspirin and ibuprofen. 6.2.3 COX-2 inhibitors in patients with coronary artery disease. 6.3 Clopidogrel use in patients requiring CABGS. 6.4 Thrombocytopenia post PCI. 6.4.1 HITTS. 6.4.2 GP2B3A risk. 6.5 Novel antiplatelet therapy. - Prasugrel etc. 7.0 Pharmacotherapy for in-stent restenosis. 7.1 Drug-eluting stents. 7.1.1 Sirolimus. 7.1.2 Paclitaxel. 7.1.3 Other agents (ABT-578). 7.1.4 Oral agents to prevent ISR (Oral Sirolimus, Glitazones). 8.0 Novel pharmacotherapy and PCI. APPENDIX. - Listing of generic drug names in alphabetical order with 1 page summary sheet on each drug. o Indications and contraindications. o Dose and formulations. o Adverse reactions. o Drug interactions
Specificaties
Uitgeverij
John Wiley and Sons Ltd
Publicatiedatum
27 november 2009
Pagina's
400
ISBN
9781405157049
Uitvoering
Hardback
Anderen kochten ook
Goodman and Gilmans Workbook to Pharmacologic Therapeutics
Je e-mailadres werd genoteerd. We informeren je wanneer dit artikel opnieuw beschikbaar is.
In welke staat is je boek?
Een belangrijke factor van een tweedehands boek is de staat van het boek. De koper mag niet voor verrassingen komen te staan. Vermeld steeds duidelijke beschadigingen of gebreken. We gebruiken een systeem met 3 sterren:
Het boek is acceptabel: je hebt het noest gebruikt om te leren en notities en markeringen aangebracht – maar alles is nog leesbaar. De kaft en pagina’s zijn in goede staat.
Het boek ziet er nog goed uit: er staan enkele notities in en je hebt er in gemarkeerd. Er zijn nauwelijks gebruikssporen aan de kaft en pagina’s.
Het boek is (zo goed als) nieuw: je hebt er niet in geschreven en niet gemarkeerd. Er zijn geen gebruikssporen aan de kaft en pagina’s.
Voor deze download heb je een code nodig.
Je code is niet correct. Probeer het opnieuw.
Meld je aan
Nog niet geregistreerd?
Registreer je om een Acco-aandeel aan te kopen of te koppelen en geniet meteen van korting. Inloggen/registreren is ook nodig om bepaalde bestanden te downloaden.